Edgewise Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edgewise Therapeutics (EWTX).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

10Buy

3Hold

Consensus RatingOutperform# Analysts13Avg. Consensus PT$47Upside to Avg. PT+18.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Sep 21, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	PT Raise	Buy	$45→$57
Aug 20, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$53→$60
Aug 11, 2026	Goldman Sachs	Paul Choi	PT Raise	Neutral	$32→$36
Jul 20, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$45→$55
Jul 9, 2026	Oppenheimer	Mazahir Alimohamed	Initiate	Outperform	$51
Jul 6, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$41→$51
Jun 17, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$48→$59
Jun 17, 2026	Goldman Sachs	Paul Choi	PT Raise	Neutral	$20→$32
Jun 16, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	Maintained	Buy	$45
Jun 2, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	PT Raise	Buy	$42→$45
Jun 2, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$50→$48
Jun 2, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$46→$52
Mar 17, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$34→$45
Mar 17, 2026	Wedbush	Laura Chico	Maintained	Outperform	$32
Feb 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$30→$45
Nov 14, 2025	JP Morgan	Tessa Romero	PT Raise	Overweight	$33→$34
Nov 7, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$49→$50
Nov 7, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$35→$32
Sep 25, 2025	Goldman Sachs	Paul Choi	Initiate	Neutral	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $51.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.

Benzinga Newsdesk

Edgewise Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Edgewise Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

People Also Watch

People Also Watch

Edgewise Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Edgewise Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWilliam Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating

PROHC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

PROGoldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PROEvercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PROOppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PROGuggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

People Also Watch

People Also Watch

PRO
William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51